Evidence map›Paper›PMID 32235008›Full record

ArticleGut and liver2021

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.

Young Hoon Choi, Sang Hyub Lee, Min Su You, Bang Sup Shin, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Wooil Kwon, Jin-Young Jang, Sun-Whe Kim

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05262452 (Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05262452 naunknown statusnot on this map

Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial

TypeinterventionalSponsorSeoul National University HospitalRan2021 to 2024Enrolled60ConditionsPancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound TherapyArmsALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Young Hoon ChoiDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2633-1401
Sang Hyub LeeDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-2174-9726
Min Su YouDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8775-6131
Bang Sup ShinDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-3702-6760
Woo Hyun PaikDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8708-3280
Ji Kon RyuDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8798-0491
Yong-Tae KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4842-6874
Wooil KwonDepartment of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4827-7805
Jin-Young JangDepartment of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3312-0503
Sun-Whe KimDepartment of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-6315-6019
Seoul National University Hospital · KRNew Generation University College · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThere has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors.

methodsBetween January 2013 and April 2017, patients with BR or LA pancreatic cancer who received FOLFIRINOX as their initial treatment were identified. Demographic data and clinical outcomes, including the chemotherapy response, conversion to resection, and survival, were reviewed.

resultsA total of 117 patients with BR (n=39) or LA (n=78) pancreatic cancer were included. Of these patients, 29 (24.8%) underwent curative surgery, and R0 resection was achieved in 21 patients (72.4%). The median progression-free survival and overall survival time of all patients were 11.6 and 19.0 months, respectively. In resected patients, the median relapse-free survival and overall survival times were 14.8 and 28.6 months, respectively. In the multivariate Cox model, the lowest level of serum carbohydrate antigen 19-9 (CA 19-9) and resection after FOLFIRINOX were independent factors for improved overall survival. In the subgroup analysis of patients with initial

conclusionsIn patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival. In these patients, the prognosis can be estimated using the lowest level of serum CA 19-9, operative status, and initial FDG-PET SUVmax.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsFluorouracilHumansIrinotecanLeucovorinNeoadjuvant TherapyNeoplasm Recurrence, LocalOxaliplatinPrognosisRetrospective StudiesFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinFOLFIRINOXNeoadjuvant therapyPancreatic neoplasmsPrognosisSurvival

Identifiers

PMID32235008
PMCPMC7960979
OpenAlexW3014175209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.